Vortioxetine-bupropion

From Psychiatrienet
Revision as of 16:49, 11 March 2015 by Walter (talk | contribs)
Jump to: navigation, search
Vortioxetine
Type Antidepressant
Group SMS
links
Medscape Vortioxetine
PubChem 9966051
PubMed Vortioxetine
Kompas (Dutch) Vortioxetine
Wikipedia Vortioxetine
Bupropion
Type Antidepressant
Group other
links
ATC-code N06AX12
Medscape Bupropion
PubChem 444
PubMed Bupropion
Kompas (Dutch) Bupropion
Wikipedia Bupropion

Switch medication from vortioxetine to bupropion.[1] [2]

Nietinrijdenbord.png Stop vortioxetine
  • Day 1: reduce dosage of vortioxetine to 5 mg/day.
  • Day 7: stop administration of vortioxetine.
Eenrichtingbord.png Start bupropion
  • Day 8: start administration of bupropion in a dosage of 150 mg/day.
Infobord.png More information
  • Bupropion is a strong inhibitor of CYP2D6, which metabolizes vortioxetine. Combination of vortioxetine and bupropion can lead to adverse effects of vortioxetine.
  • Vortioxetine has a biological half-life of 66 hours. Reduction to the lowest effective dose of vortioxetine probably prevents adverse effects of vortioxetine due to lower blood levels of vortioxetine.
  1. Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
  2. Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.